PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China.\', \'National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu 610041, China.\', \'National Institute of Food and Drug Control, Beijing 100050, China.\', \'Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.\', \'The Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China.\', \'National Institute of Food and Drug Control, Beijing 100050, China. Electronic address: changguili@aliyun.com.\', \'Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China. Electronic address: cheyanchun@imbcams.com.cn.\', \'Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China. Electronic address: liuld@imbcams.com.cn.\', \'Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, China. Electronic address: liqihan@imbcams.com.cn.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)00431-X10.1016/j.vaccine.2021.04.006
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 33875266
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C0014892_interactsWith_C0000588>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C0014892_interactsWith_C0000588>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all